By: Ryan McDonald From: curetoday.com Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S. Treatment with oral endoxifen during the “window of opportunity” between breast cancer diagnosis and …